{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-144146","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.804782+00:00","generated_at":"2026-06-15T01:27:47.682315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Disc Medicine Q1 net loss $22.8M, cash $236.4M; pipeline catalysts on track","bullets":["Net loss $22.8M in Q1 2023 vs $9.9M in Q1 2022; R&D expenses $20.2M including $10M Mabwell upfront.","Cash and equivalents $236.4M at March 31, 2023, up from $194.6M; funding expected into 2025.","Bitopertin Phase 2 BEACON interim data at EHA June 9, 2023; topline from BEACON and AURORA by end 2023.","DISC-0974 Phase 1b/2 in NDD-CKD and MF anemia; interim data expected by end of 2023.","In-licensed anti-TMPRSS6 mAbs from Mabwell; Phase 1 trial planned for second half 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-144146","json":"https://secwatch.observer/filing/0001193125-23-144146.json","markdown":"https://secwatch.observer/filing/0001193125-23-144146.md","text":"https://secwatch.observer/filing/0001193125-23-144146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/0001193125-23-144146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/d481241d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:27:47.682315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e40d3c52247f191da400a1c6eb393a9fce50bfe2","claim":"Disc Medicine, Inc. reported financial results for first quarter ending March 31, 2023.","evidence_excerpt":"Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/0001193125-23-144146-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ending March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}